Atea Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Atea Pharmaceuticals

08/05/2023 23:05

* Atea Pharmaceuticals Inc  AVIR.OQ  reported a quarterly
adjusted
loss of 43 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 48 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Atea Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 43 cents​.
    * The mean earnings estimate of analysts had risen by
about 8.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Atea Pharmaceuticals Inc shares had held steady so far
this
quarter and lost 30.4% so far this year.
    * The company reported a quarterly loss of $35.47 million.
    * Wall Street's median 12-month price target for Atea
Pharmaceuticals Inc is $4.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
8 at 10:05 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.48          -0.43          Beat
 Dec. 31 2022      -0.45          -0.41          Beat
 Sep. 30 2022      -0.44          -0.10          Beat
 Jun. 30 2022      -0.52          -0.38          Beat